Abbott’s HUMIRA(R) (Adalimumab) Receives Positive Opinion From European Medicines Agency For The Treatment Of Ankylosing Spondylitis

Abbott today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), granted a positive opinion recommending approval of HUMIRA(R) (adalimumab) for the treatment of severe active ankylosing spondylitis. The…

Read More

Abbott’s New Tablet Formulation Of Kaletra(R) (Lopinavir/Ritonavir) Receives Positive Opinion From The European Medicines Agency

Abbott announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has issued a positive opinion recommending approval of a new, more convenient tablet formulation of its protease inhibitor…

Read More

Pharmacokinetic Data For Nastech’s Intranasal Parathyroid Hormone (PTH1-34) Demonstrated Similar Profile To Approved Injectable Product

Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) presents data today from a Phase I pharmacokinetic study of Parathyroid Hormone (PTH1-34) nasal spray demonstrating a similar pharmacokinetic profile to the approved subcutaneous product, Forteo(R) (teriparatide). The data are being presented at the…

Read More

Clinical Utility Of Two Novel Genes That Can Identify Patients At Higher Risk For Early Breast Cancer Recurrence

AviaraDx, Inc., formerly known as Arcturus Bioscience, Inc., a leader in molecular cancer profiling, announced today that a study, conducted in collaboration with Mayo Clinic, demonstrated the clinical utility of two novel genes that can identify patients at higher risk…

Read More

Positive Phase II Results With Orally Active GnRH Receptor Antagonist In Endometriosis – Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced positive results of its ‘proof of concept’, safety, efficacy and dose-finding Phase II clinical trial using its proprietary, orally-active small molecule Gonadotropin-Releasing Hormone (GnRH) receptor antagonist (NBI-56418). The 3-month data comes from a…

Read More

New Research Identifies Specific Teenage And Young Adult Cancers And Points To Possible Causes

An analysis of new data by a leading cancer researcher has revealed specific cancers that are most likely to affect teenagers and young adults, and it points to infections, adolescent growth spurts, and hormones as being among the possible causes.…

Read More